Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines.

Trial Details

NCT ID

NCT06326736

Phase

EARLY_PHASE1

Sponsor

Jinling Hospital, China

Status

RECRUITING

Cancer Type

Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

Interventions

Surgery
Camrelizumab
SJ-Neo006
Gemcitabine+Abraxane

Locations (sample)

Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

Subjects voluntarily participate in this clinical study and sign the Informed Consent Form (ICF).
Subjects must be \>/= 18 years of age at time of informed consent.
Subjective with radiographically resectable primary pancreatic tumors with radiographic features consistent with adenocarcinoma will be evaluated f…
Subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1) will be selected f…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →